Enlarge / The exterior of the headquarters of biotechnology company Biogen in Cambridge, Massachusetts. (credit: Getty | Boston Globe) Biogen’s new Alzheimer’s drug Aduhelm continues to face opposition after its contentious approval from the Food and Drug Administration last month—which the FDA now says should be independently investigated. Some insurers say they won’t pay for […]
